Management of Diabetes in CKD: 2020 KDIGO Guidelines and Beyond. Prof. Hussein Sheashaa, 14 Oct 2020 

Management of Diabetes in CKD: 2020 KDIGO Guidelines and Beyond,14 Oct 2020
0:00 Introduction
October 2020 KDIGO for management of diabetes in chronic kidney disease
1:26 Introduction to October 2020 KDIGO Guidelines
5:13 Lifestyle modification
11:35 The use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers
19:51 Glycemic monitoring and target
22:41 Antihyperglycemic therapy
31:09 Team based integrated care
SGLT2- inhibitors update till 14 Oct 2020
32:10 dapagliflozin (DAPA-CKD Trial)
38:04 DAPA in albuminuric type 1 diabetes, Empagliflozin in KDIGO-CKD risks.
39:09 Ertugliflozin (VERTIS-CV Trial), Pharmacology and cardiovascular risk reduction in type 2 diabetes and metanalysis for assessing if class effect is true and consensus statements
45:07 SGLT2 inhibitors and HIF1 and 2
46:28 Euglycemic DKA
49:12 Kidney biopsy in diabetes
51:28 Progression of CKD
53:09 AKI in diabetes
53:27 Hypoglycemia and arrhythmia
56:48 COVID-19 and diabetes management and closing
Speaker:
Prof. Hussein Sheashaa,
Professor of Nephrology, Urology and Nephrology Center, Mansoura University, ESNT-CME and Distance Learning Chapter Chair
Join our Facebook group: / 1070654119793265
Follow me on Facebook: / hussein.sheashaa
Follow me on Instagram: / husseinsheashaa